Immunotherapy Eliminates Early-Stage Tumors Without Surgery in 82% of Patients
Groundbreaking study shows PD-1 blockade achieves complete tumor elimination in most mismatch repair-deficient cancers, avoiding surgery.
Summary
A landmark study of 117 patients with early-stage mismatch repair-deficient (MMRd) tumors found that 6 months of dostarlimab immunotherapy eliminated tumors completely in 82% of cases, allowing patients to avoid surgery entirely. All 49 rectal cancer patients achieved complete responses, while 65% of non-rectal solid tumors responded completely. With 20-month median follow-up, 92% remained recurrence-free. This represents the first tumor-agnostic demonstration that immunotherapy alone can cure early-stage cancers without surgery, potentially transforming treatment for the 2-10% of solid tumors that are MMRd.
Detailed Summary
This groundbreaking study demonstrates that immunotherapy can eliminate early-stage cancers without surgery across multiple tumor types. Researchers treated 117 patients with mismatch repair-deficient (MMRd) solid tumors using dostarlimab, a PD-1 blocking immunotherapy, for 6 months before planned surgery.
The results were remarkable: 84 of 103 patients (82%) who completed treatment achieved complete clinical responses, with 82 patients (80%) choosing to forgo surgery entirely. In rectal cancers specifically, all 49 patients achieved complete responses and avoided surgery. Among 54 non-rectal solid tumors (including gastric, colon, bladder, and gynecologic cancers), 35 patients (65%) achieved complete responses.
Crucially, no patients progressed to unresectable disease during treatment, addressing a key safety concern. At median 20-month follow-up, two-year recurrence-free survival was 92% (86-99% confidence interval). Side effects were predominantly low-grade, occurring in about 20% of patients. Even patients with incomplete responses showed significant tumor regression (87% of resected specimens).
This study extends previous rectal cancer findings to a broader range of tumor types, mirroring how immunotherapy benefits MMRd cancers in metastatic settings. The approach could transform treatment for the estimated 2-10% of early-stage solid tumors that are mismatch repair-deficient, offering organ preservation and avoiding surgical morbidity while maintaining cure rates.
Key Findings
- Complete clinical response achieved in 84 of 103 patients (82%, 95% CI: 72-88%) across tumor types
- All 49 rectal cancer patients (100%) achieved complete response and avoided surgery
- 65% of non-rectal solid tumors (35 of 54 patients) achieved complete clinical response
- Two-year recurrence-free survival was 92% (86-99% CI) at median 20-month follow-up
- Zero patients progressed to unresectable disease during 6-month treatment period
- Low-grade side effects occurred in approximately 20% of patients
- 87% of incomplete responders (14 of 16) showed significant tumor regression at surgery
Methodology
Prospective study of 117 patients with stage I-III mismatch repair-deficient solid tumors treated with dostarlimab 500mg IV every 3 weeks for 9 cycles (6 months). Two cohorts: rectal cancers (n=49) and non-rectal solid tumors (n=54). Response assessed by imaging, endoscopy, and clinical examination. Statistical analysis used Simon's 2-stage design for rectal cohort with 80% power to detect improvement from 27.5% to 50% sustained response rate.
Study Limitations
Median follow-up of 20 months is relatively short for definitive long-term outcomes. The study was conducted at specialized cancer centers which may limit generalizability. MMRd tumors represent only 2-10% of solid tumors, limiting broader applicability. Authors note that longer follow-up is needed to confirm durability of responses and establish optimal surveillance protocols for patients choosing non-operative management.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.